RxDoctor Payments Data

Robert Satty

Optometrist · Neptune, NJNPI 1295892347

Payments from drug & device makers

$4,374in general payments, 2019–2025

Across 227 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$890
  • AbbVie$585
  • Biotissue Holdings Inc.$545
  • Alcon$381
  • Oyster Point Pharma, Inc.$335
  • Bausch & Lomb Americas Inc.$321
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,32099%
  • Gifts$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,374 in reported general payments places this provider in the 90th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$90,392
Medicare patients
495
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast23$44,276
RestasisCyclosporine27$37,678
TyrvayaVarenicline Tartrate21$26,521
LumiganBimatoprost37$19,501
RocklatanNetarsudil Mesylat/Latanoprost37$18,147
VyzultaLatanoprostene Bunod17$11,671
Cyclosporine24$10,505
CequaCyclosporine12$9,042
RhopressaNetarsudil Mesylate16$7,479
SimbrinzaBrinzolamide/Brimonidine Tart11$2,470
Brinzolamide14$2,160
Brimonidine Tartrate29$1,769
Latanoprost82$991
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat50$856
Fluorometholone11$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$585$57,17864 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$321$55,94740 claims
Oyster Point Pharma, Inc.Tyrvaya$335$26,52121 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$73$25,62753 claims
Sun Pharmaceutical Industries Inc.Cequa$890$9,04212 claims
AlconSimbrinza$381$2,47011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →